Oncotarget

Researchers discuss the efficacy of continuous treatment with Abemaciclib in inhibiting breast cancer cell proliferation. Abemaciclib shows higher potency than other inhibitors in inhibiting CDK4 kinase activity. It is effective regardless of HER2 status and PI3KCA gene mutation. The impact on myeloid maturation in bone marrow progenitor cells is lower compared to other inhibitors.

Learn about the genetic mutations driving Fusion Positive Rhabdomyosarcoma (FPRMS) and the role of KDM3A and ETS1 in promoting the growth and metastasis of Rhabdomyosarcoma. Discover shared disease-promoting pathways with Ewing's sarcoma and potential therapeutic targets for multiple subtypes.

Explore diverse research papers in Oncotarget Volume 13 focusing on topics like PARP inhibitors, immunotherapy, colorectal cancer, DNA breaks on memory, and nanobiotechnology for targeted therapy. Discover advancements in bladder, breast, and colorectal cancers, genetic influences on cytotoxicity, glucocorticoid receptor therapy for cancer, endometrial cancer cell growth, gene-driven endocrine resistance, treatment combinations for glioblastoma, and immunotherapy responses in specific mutations.

Explore recent cancer research on EZH2 mechanisms and cranial irradiation effects, as well as topics like molecular background of NIFTP, immunotherapy of prostate cancer, and genomic profiling of DVL1 in triple-negative breast cancer in the latest Genes & Cancer publication.

Explore the origins and impact of the Ride for Roswell event, reflecting on its history of raising funds and awareness for cancer research. Learn about Team Open Access and their dedication to fundraising for cancer research at Roswell Park Comprehensive Cancer Center.

Dr. Alexander Pohlman discusses the role of IGF-pathway biomarkers in lung cancer, focusing on their potential in risk assessment, screening, and prognosis. The podcast explores the significance of these biomarkers and their diagnostic and predictive value when combined with other screening techniques.

Discover the groundbreaking research revealing 34 novel genes linked to endocrine resistance in breast cancer, highlighting the importance and challenges of endocrine therapy for estrogen receptor positive tumors.

Researchers discuss the use of NF-κB activity to classify HPV+ head and neck cancer, highlighting the need for personalized treatment. They delve into genomic variances, TRAF3 and CYLD gene mutations, and the impact on patient outcomes. The development of a classification tool for prediction and personalized treatment strategies is crucial in improving outcomes for HPV+ HNSCC patients.

Discussion on the impact of NF Kappa B overactivation in HPV positive HNSCC, the importance of identifying TRAF3 and CYLD mutations for improved prognosis, and the use of RNA-based classification strategies.

Researchers from Louisiana State University developed CancerOmicsNet, a graph neural network model for anti-cancer drug profiling. The model integrates diverse biological data sources and shows promising results in predicting cancer cell growth after drug treatment. The study emphasizes the accuracy of CancerOmicsNet in cross-validation assessments, highlighting its potential to forecast the effects of kinase-targeted therapies on cancer cell proliferation.